Regional disparities in cost-effectiveness of biologics for CRSwNP should not modify the strategy
Volume: 64 - Issue: 2
First page: 278 - Last page: 280
M. Fieux - F. Carsuzaa - M. Chang - P.H. Hwang - Z.M. Patel - S. Tringali - V. Favier - J. Margier
DOI: 10.4193/Rhin25.548
Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a significant burden on the healthcare system. Xian et al. discussed several aspects of our economic model, based on French pricing, that may impact the cost-effectiveness of biologics . Briefly, they outlined the regional disparities in the cost of biologics, the potential better outcomes of biologics in real-world evidence, and the recurrence rate after endoscopic sinus surgery (ESS). We think that these aspects may be further discussed.
Rhinology 64 - 2: 278-280, 2026
To see the issue content and the abstract you do not have to login
Please login to download the full articles
If you do not have a subscription to Rhinology please consider taking one.
